319 reports of this reaction
2.1% of all TERBINAFINE HYDROCHLORIDE reports
#7 most reported adverse reaction
AGEUSIA is the #7 most commonly reported adverse reaction for TERBINAFINE HYDROCHLORIDE, manufactured by Aurobindo Pharma Limited. There are 319 FDA adverse event reports linking TERBINAFINE HYDROCHLORIDE to AGEUSIA. This represents approximately 2.1% of all 14,851 adverse event reports for this drug.
Patients taking TERBINAFINE HYDROCHLORIDE who experience ageusia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
AGEUSIA is a less commonly reported adverse event for TERBINAFINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to ageusia, the following adverse reactions have been reported for TERBINAFINE HYDROCHLORIDE:
The following drugs have also been linked to ageusia in FDA adverse event reports:
AGEUSIA has been reported as an adverse event in 319 FDA reports for TERBINAFINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
AGEUSIA accounts for approximately 2.1% of all adverse event reports for TERBINAFINE HYDROCHLORIDE, making it a notable side effect.
If you experience ageusia while taking TERBINAFINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.